@article{573abd5221564f9abacc751b43fc68df,
title = "2nd ESMO Consensus Conference on Lung Cancer: Non-small-cell lung cancer first-line/second and further lines in advanced disease",
abstract = "To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, early stage disease and locally-advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on 1st line / 2nd and further lines of treatment in advanced disease.",
keywords = "Consensus, Esmo, Further lines, Non-small-cell lung cancer",
author = "Benjamin Besse and A. Adjei and P. Baas and P. Meldgaard and M. Nicolson and L. Paz-Ares and M. Reck and Smit, {E. F.} and Konstantinos Syrigos and R. Stahel and E. Felip and S. Peters and Keith Kerr and Johan Vansteenkiste and Wilfried Eberhardt and Martin Edelman and Tony Mok and Ken O'Byrne and Silvia Novello and Lukas Bubendorf and Antonio Marchetti and Paul Baas and Martin Reck and Peter Meldgaard and Alex Adjei and Marianne Nicolson and Lucio Crin{\`o} and {Van Schil}, Paul and Suresh Senan and Corinne Faivre-Finn and Gaetano Rocco and Giulia Veronesi and Douillard, {Jean Yves} and Eric Lim and Christophe Dooms and Walter Weder and {De Ruysscher}, Dirk and {Le Pechoux}, Cecile and {De Leyn}, Paul and Virginie Westeel",
note = "Funding Information: RS has reported Consultancy/honoraria: Abbott, Amgen, Astellas, Boehringer Ingelheim, Daiichi-Sankyo, GlaxoSmithKline, Genentech, Eli Lilly, Roche. EF has reported Consultancy/ honoraria: Lilly, GlaxoSmithKline, Pfizer, Roche, Boehringer Ingelheim. SP has reported Consultancy/honoraria: Roche, Eli Lilly, AstraZeneca, Pfizer, Boehringer Ingelheim, Bristol-Myers Squibb, Merck Serono, Daiichi-Sankyo, Tesaro. KK has reported Speakers{\textquoteright} bureau: Abbott Diagnostics, Roche, AstraZeneca, Eli Lilly, Pfizer. BB has reported Research grants: Pfizer, Roche, Boehringer Ingelheim, AstraZeneca. JV has reported that he is the Eli Lilly Chair in Respiratory Oncology at the Leuven University (research funding) and is the AstraZeneca Chair in Personalised Lung Cancer Care at the Leuven University (research funding). WE has reported Advisory board: GlaxoSmithKline, Amgen, Novartis, Merck, Teva, Roche, AstraZeneca, Lilly, Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb; Speakers{\textquoteright} bureau: Roche, AstraZeneca, Lilly, Boehringer Ingelheim, Pfizer, GlaxoSmithKline, Amgen, Novartis, Hexal, Merck; Research grants: Eli Lilly. ME has reported Advisory board and/or research funding: Genentech, Boehringer Ingelheim, Lilly, Endocyte. PB has reported Research grants: Pfizer. MR has reported Advisory board: Hoffmann-La Roche, Lilly, Pfizer, AstraZeneca, Bristol-Myers Squibb, Daiichi-Sankyo; Speakers{\textquoteright} honoraria: Hoffmann-La Roche, Lilly, Pfizer, Bristol-Myers Squibb, AstraZeneca, Daiichi-Sankyo. LP-A has reported Scientific advisor/ Speakers{\textquoteright} bureau: Lilly, Roche, Pfizer, Merck, Boehringer Ingelheim, Desi pharma, Celgene. PM has reported Speakers{\textquoteright} bureau: Roche. MN has reported Speakers{\textquoteright} bureau: Roche, Lilly, Boehringer Ingelheim, Pfizer, Otsuka; Research grants: Roche, Lilly, Boehringer Ingelheim, Pfizer, Novartis. SS has reported Research grants and honoraria: Varian Medical Systems; member of phase III trial management group conducted by Lilly Oncology. CF-F has reported Research grants AstraZeneca, Eli Lilly. GR has reported Speakers{\textquoteright} bureau/grants: Covidien. EL has reported Research support: ScreenCell and PointHope; previously Speakers{\textquoteright} bureau for Roche and Imedex and Advisory board for Strategen, Abbott Molecular and GlaxoSmithKline; patent pending with Clearbridge BioMedics; stock in Pfizer. VW has reported Consultancy/honoraria: Lilly, Roche, Boehringer Ingelheim and AstraZeneca (for lectures); Advisory role: Lilly, Roche and AstraZeneca; currently conducting research sponsored by Merck Serono. TM has reported: Speakers{\textquoteright} bureau and Honoraria from: AstraZeneca, Roche, Eli Lilly, Merck Serono, Eisai, Bristol-Myers Squibb, BeiGene, AVEO, Pfizer, Taiho, Boehringer Ingelheim, GlaxoSmithKline Biologicals, Clovis Oncology; Research funding from AstraZeneca. LB has reported Speakers{\textquoteright} honoraria: Pfizer, Roche, and Abbott Molecular, Inc.; research supported by and stock held in Roche. SN, AM, KS, EFS, AA, PVS, J-YD, WW, DDR, CLP, PDL, GV and CD have declared no potential conflicts of interest. LC and KO{\textquoteright}B have not reported any potential conflicts of interest.",
year = "2014",
month = aug,
day = "1",
doi = "10.1093/annonc/mdu123",
language = "English (US)",
volume = "25",
pages = "1475--1484",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "8",
}